Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Cash from Financing Activities (2022 - 2025)

Historic Cash from Financing Activities for 60 Degrees Pharmaceuticals (SXTP) over the last 4 years, with Q3 2025 value amounting to $4.3 million.

  • 60 Degrees Pharmaceuticals' Cash from Financing Activities fell 1685.37% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year decrease of 1520.78%. This contributed to the annual value of $7.1 million for FY2024, which is 894.28% up from last year.
  • Per 60 Degrees Pharmaceuticals' latest filing, its Cash from Financing Activities stood at $4.3 million for Q3 2025, which was down 1685.37% from $1.7 million recorded in Q1 2025.
  • In the past 5 years, 60 Degrees Pharmaceuticals' Cash from Financing Activities registered a high of $6.0 million during Q3 2023, and its lowest value of -$68629.0 during Q4 2022.
  • In the last 4 years, 60 Degrees Pharmaceuticals' Cash from Financing Activities had a median value of $1.0 million in 2023 and averaged $1.9 million.
  • Examining YoY changes over the last 5 years, 60 Degrees Pharmaceuticals' Cash from Financing Activities showed a top increase of 94353.96% in 2024 and a maximum decrease of 10026.94% in 2024.
  • Over the past 4 years, 60 Degrees Pharmaceuticals' Cash from Financing Activities (Quarter) stood at -$68629.0 in 2022, then surged by 8800.56% to $6.0 million in 2023, then tumbled by 99.98% to $973.0 in 2024, then surged by 440000.51% to $4.3 million in 2025.
  • Its Cash from Financing Activities was $4.3 million in Q3 2025, compared to $1.7 million in Q1 2025 and $973.0 in Q4 2024.